Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects
NCT ID: NCT00541762
Last Updated: 2015-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2006-01-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: The aim of this study was therefore to investigate whether CCK mediated the effect of intraduodenal (ID) fat on neurotensin secretion via CCK-1 receptors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans
NCT02537314
Effects of High-fat and Low-fat Diet on the Gut
NCT00561626
Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People
NCT01456572
Glucose-stimulated Gut Lipid Release
NCT03464240
Postprandial Hemodynamics
NCT01027507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects receiving an ID fat infusion with or without 60 mg orlistat, an irreversible inhibitor of gastrointestinal lipases, in comparison to vehicle. 2) 12 subjects receiving ID long chain fatty acids (LCF), ID medium chain fatty acids (MCF) or ID vehicle. 3) 10 subjects receiving ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (DEXLOX) or ID vehicle plus IV saline (placebo). Hormone concentrations were measured by specific RIA systems.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A, 3; B, 3; C, 3
A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
Fat perfusion to the small intestine
1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine
2. Orlistat perfused to the small intestine
3. DEXLOX as CCK-1 receptor antagonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fat perfusion to the small intestine
1. Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine
2. Orlistat perfused to the small intestine
3. DEXLOX as CCK-1 receptor antagonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juergen Drewe, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, 4031 Basel, Switzerland
Christoph Beglinger, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Research and Clinical Pharmacology, University Hospital, Basel Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Center, University Hospital
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ferris CF, Carraway RE, Hammer RA, Leeman SE. Release and degradation of neurotensin during perfusion of rat small intestine with lipid. Regul Pept. 1985 Oct;12(2):101-11. doi: 10.1016/0167-0115(85)90191-0.
Related Links
Access external resources that provide additional context or updates about the study.
publication in JCEM
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNF Grant. 3200-065588.04/1
Identifier Type: -
Identifier Source: secondary_id
EKBB 86/05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.